Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

NT-pro BNP : A new diagnostic screening tool for Kawasaki disease

가와사끼병에서 진단적 지표로서의 NT-proBNP

  • Lee, Hyunju (Department of Pediatrics, Ewha Womans University College of Medicine) ;
  • Kim, Heejung (Department of Pediatrics, Ewha Womans University College of Medicine) ;
  • Kim, Hae Soon (Department of Pediatrics, Ewha Womans University College of Medicine) ;
  • Sohn, Sejung (Department of Pediatrics, Ewha Womans University College of Medicine)
  • 이현주 (이화여자대학교 의과대학 소아과학교실) ;
  • 김희정 (이화여자대학교 의과대학 소아과학교실) ;
  • 김혜순 (이화여자대학교 의과대학 소아과학교실) ;
  • 손세정 (이화여자대학교 의과대학 소아과학교실)
  • Received : 2005.12.23
  • Accepted : 2006.02.15
  • Published : 2006.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The purpose of this study was to determine whether N-terminal fragment of B-type natriuretic peptide(NT-proBNP) may be used to differentiate acute Kawasaki disease(KD) from other clinically similar diseases. Methods : Using electrochemiluminescence immunoassay, NT-proBNP concentrations were measured in the acute phase within 10 days after the onset of KD(n=58) and in the convalescent phase, 60 to 81 days after the onset(n=51), and also in patients with acute febrile disease as a control(n=34). Echocardiography was performed to detect pericardial effusion(PE) and coronary artery lesions(CAL), and to measure the left ventricular dimension at diastole(LVIDd) and ejection fraction(LVEF). The cutoff value of NT-proBNP for separating KD from other diseases was determined. Results : NT-proBNP concentration in the acute phases of KD was significantly higher than that in the control group($1,501.6{\pm}2,132.6$ vs. $139.0{\pm}88.8pg/mL$, P<0.0001). In KD patients, NT-proBNP was elevated in the acute phase and was lowered in the convalescent phase($1,466.0{\pm}2,173.2$ vs. $117.5{\pm}95.5pg/mL$, P<0.0001). The cutoff value of 260 pg/mL discriminated KD patients from other patients, with a sensitivity of 93 percent and a specificity of 88 percent. The NT-proBNP was higher in patients with PE(n=17) compared with those without PE(n=41)($1,784.2{\pm}1,903.1$ vs. $1,384.4{\pm}2,232.6pg/mL$, P=0.52). Comparison of NT-proBNP could not be done between patients with CAL and those without, owing to a small number of patients with CAL(n=3). There was no correlation between NT-proBNP and LVEF index(r=0.104, P=0.46) or LVIDd index(r=0.171, P=0.22). Conclusion : NT-proBNP increases in the acute phase of KD and decreases to within normal range in the convalescent phase. NT-proBNP >260 pg/mL may be highly suggestive of acute KD. NT-proBNP may be used as a diagnostic tool for KD.

목 적 : 가와사끼병의 진단 지표로서 NT-proBNP의 유용성을 살펴보고자 하였다. 방 법 : 가와사끼병을 진단 받은 환아 58명에서 발병 10일 이내 급성기에 전기화학발광면역법(Electrochemiluminescence immunoassay)를 이용하여 NT-proBNP를 측정하였고, 그 중 51명에서 회복기(발병 60에서 81일 이내)에 NT-proBNP 값을 측정하여 비교하였다. 가와사끼병과 임상적으로 구별하기 어려운 급성 열성 질환이 있는 환아 34명을 대조군으로 하여 NT-proBNP를 측정하여 가와사끼병 환자군과 비교하였다. 또한 가와사끼병 급성기에 심장 초음파검사를 시행하여 심낭삼출과 관상동맥 병변의 여부를 확인하였고 좌심실 확장기말 내경(LVIDd)과 수축기말 내경(LVIDs), 좌심실 구출율(LVEF)과 좌심실 단축율(LVSF)을 측정하여 NT-proBNP 측정치와의 상관관계를 조사하였다. 가와사끼병과 다른 질환의 감별진단을 위해 receiveroperating characteristic curve를 이용하여 NT-proBNP의 cutoff value를 구하였다. 결 과 : 가와사끼병 급성기 NT-proBNP 측정치는 대조군에 비해 유의하게 높았다($1,501.6{\pm}2,132.6$ vs. $139.0{\pm}88.8pg/mL$, P<0.0001). 51명의 가와사끼병 환자군에서 NT-proBNP 값은 급성기에 증가하고 회복기에 크게 감소하였다($1,466.0{\pm}2,173.2$ vs. $117.5{\pm}95.5pg/mL$, P<0.0001). 가와사끼병의 감별진단을 위한 NT-proBNP의 cutoff value를 260 pg/mL으로 하였을 때 민감도 93%, 특이도 88%를 보였다. NT-proBNP는 심낭삼출이 있는 환아에서 심낭삼출이 없는 환아에 비해 높았다($1,784.2{\pm}1,903.1$ vs. $1,384.4{\pm}2,232.6pg/mL$). 관상동맥 병변이 있는 환아(n=3)가 적어 NT-proBNP와의 관계를 확인할 수 없었다. NT-proBNP 측정치와 LVEF index(r=0.104, P=0.46) 및 LVIDd index(r=0.171, P=0.22)은 상관관계가 없었다. 결 론 : NT-proBNP는 가와사끼병 급성기에 크게 증가하며 회복기에 감소한다. NT-proBNP >260 pg/mL일 때 가와사끼병을 강력히 의심할 수 있으며, NT-proBNP는 가와사끼병을 진단하는 지표로 사용될 수 있을 것으로 생각된다.

Keywords

Acknowledgement

Supported by : 이대목동병원

References

  1. Cowie M, Mendez G. BNP and congestive heart failure. Curr Probl Cardiol 2003;44:264-310
  2. Cowie M, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, et al. Clinical applications of B-type natriuretic peptide(BNP) testing. Eur Heart J 2003;24:1710-18 https://doi.org/10.1016/S0195-668X(03)00476-7
  3. Groenning BA, Nilsson JC, Sondergaard L, Kjaer A, Larsson HB, Hildebrandt PR. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001;3:699-708 https://doi.org/10.1016/S1388-9842(01)00181-7
  4. Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990;323:757-8 https://doi.org/10.1056/NEJM199009133231114
  5. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 2004;6:289-93 https://doi.org/10.1016/j.ejheart.2003.12.012
  6. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail 2004;6:257-60 https://doi.org/10.1016/j.ejheart.2003.12.015
  7. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and longterm management of Kawasaki disease. Circulation 2004; 110:2747-71 https://doi.org/10.1161/01.CIR.0000145143.19711.78
  8. Rowley AH. Incomplete (atypical) Kawasaki disease. Pediatr Infect Dis J 2002;21:563-5 https://doi.org/10.1097/00006454-200206000-00015
  9. Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Ministry of Health and Welfare, Tokyo, 1984
  10. Peduzzi TL, Pitetti RD. Myocardial infarction and atypical Kawasaki disease in a 3-month-old infant. Pediatr Emerg Care 2002;18:16-9 https://doi.org/10.1097/00006565-200210000-00008
  11. Kawamura T, Masakuni W, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000;42:241-8 https://doi.org/10.1046/j.1442-200x.2000.01225.x
  12. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91 https://doi.org/10.1161/01.CIR.88.1.82
  13. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004;36:505-13 https://doi.org/10.1016/j.yjmcc.2004.01.001
  14. Suzuki H, Uemura S, Tone S, Iizuka T, Koike M, Hirayama K, et al. Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr 1996;155: 291-6 https://doi.org/10.1007/BF02002715
  15. Sato N, Sagawa K, Sasaguri Y, Inoue O, Kato H. Immunopathology and cytokine detection in the skin lesions of patients with Kawasaki disease. J Pediatr 1993;122:198-203 https://doi.org/10.1016/S0022-3476(06)80113-7
  16. Maury CPJ, Salo E, Pelkonen P. Circulating interleukin- 1beta in patients with Kawasaki disease. N Engl J Med 1988;319:1670-1 https://doi.org/10.1056/NEJM198812223192515
  17. Kawamura T, Wago M. Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. Cardiol Young 2002;12:153-8 https://doi.org/10.1017/S1047951102000318
  18. Harada E, Nakagawa O, Yoshimura M, Harada M, Nakagawa M, Mizuno Y, et al. Effect of interleukin-1beta on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. J Mol Cell Cardiol 1999;31:1997-2006 https://doi.org/10.1006/jmcc.1999.1030
  19. Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-terminal pro-B-type natriuretic peptide : reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart disease. Acta Paediatr 2004;93:603-7 https://doi.org/10.1080/08035250410025799
  20. Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002;110:e76 https://doi.org/10.1542/peds.110.6.e76
  21. Rowley AH, Shulman ST. Kawasaki disease. In : Behrman RE, Kliegman RM, Jenson HB, editors. Nelson textbook of pediatrics. 17th ed. Philadelphia : WB Saunders Co, 2004: 823-6
  22. Takahashi M. Kawasaki syndrome(mucocutaneous lymph node syndrome). In : Allen HD, Gutgesell HD, Clark EB, Driscoll DJ, editors. Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adults. 6th ed. Philadelphia : Lippincott Williams & Wilkins Co, 2001:1216-25
  23. Nakagawa O, Ogawa Y, Hiroshi I, Suga S, Komatsu Y, Kishimoto I, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an 'emergency' cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7 https://doi.org/10.1172/JCI118162
  24. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of pro-brain natriuretic peptide(Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175-83 https://doi.org/10.1006/bbrc.1995.2410
  25. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362: 316-22 https://doi.org/10.1016/S0140-6736(03)13976-1
  26. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80 https://doi.org/10.1161/01.CIR.87.5.1776
  27. Cardarelli R, Lumicao TG Jr. B-type natriuretic peptide : A review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract 2003;16:327-33 https://doi.org/10.3122/jabfm.16.4.327
  28. Bonow RO. New insights into the cardiac natriuretic peptides. Circulation 1996;93:1946-50 https://doi.org/10.1161/01.CIR.93.11.1946
  29. Rauh M, Koch A. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem 2003;49:1563-4 https://doi.org/10.1373/49.9.1563